BR-112023023114-B1 - SUPPLEMENT TO REDUCE ALLERGIC RESPONSE TO Fel-D1, ITS MANUFACTURING METHOD, AND SYSTEM TO REDUCE ALLERGIC RESPONSE TO Fel-D1

BR112023023114B1BR 112023023114 B1BR112023023114 B1BR 112023023114B1BR-112023023114-B1

Abstract

FOOD SUPPLEMENTS FOR CATS COMPRISING AN ANTI-FEL-D1 MOLECULE AND ANIMAL DIGEST. Most allergies in cats are caused by a small, stable glycoprotein called Fel-D1, which is transferred to the cat's dander through its grooming process and is carried by the air. It is possible to reduce this phenomenon by feeding the cat a supplement comprising anti-Fel-D1 molecules and an animal digest. The present invention relates to compositions, methods, and systems developed for this purpose.

Inventors

MAUD ISABELLE LALLEMAND
Ivan Filipi

Assignees

SOCIÉTÉ DES PRODUITS NESTLÉ S.A

Dates

Publication Date: 20260310
Application Date: 20220428
Priority Date: 20210517

Claims (6)

1. Supplement to reduce the allergic response to Fel-D1, characterized in that it comprises dried egg yolk powder, which comprises an anti-Fel-D1 molecule, which is specific anti-Fel-D1 polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest, which is a heat-treated enzymatic hydrolysate based on meat, wherein the dried egg yolk powder is present in an amount of 1% by weight to 30% by weight of the supplement; wherein the anti-Fel-D1 molecule is present in an amount of 0.0001% by weight to 1% by weight of the supplement; and wherein the dried animal digest is present in an amount of 20% by weight to 80% by weight of the supplement.
2. Supplement, according to claim 1, characterized in that it further comprises an additive selected from the group consisting of vitamin E, vitamin C and mixtures thereof.
3. Method for manufacturing a supplement to reduce the allergic response to Fel-D1, characterized in that it comprises mixing (i) dried egg yolk powder, comprising an anti-Fel-D1 molecule, which is specific anti-Fel-D1 polyclonal immunoglobulin Y (sIgY), and (ii) a dried animal digest, which is a heat-treated enzymatic hydrolysate based on meat, to form the supplement, wherein the dried egg yolk powder is present in an amount of 1% by weight to 30% by weight of the supplement; wherein the anti-Fel-D1 molecule is present in an amount of 0.0001% by weight to 1% by weight of the supplement; and wherein the dried animal digest is present in an amount of 20% by weight to 80% by weight of the supplement.
4. A method according to claim 3, characterized in that it further comprises mixing an additive selected from the group consisting of vitamin E, vitamin C, and mixtures thereof.
5. System for reducing the allergic response to Fel-D1, characterized in that it comprises: a food composition, and a supplement, wherein the supplement comprises dried egg yolk powder, which comprises an anti-Fel-D1 molecule, which is specific anti-Fel-D1 polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest, which is a heat-treated enzymatic hydrolysate based on meat, wherein the dried egg yolk powder is present in an amount of 1% by weight to 30% by weight of the supplement; wherein the anti-Fel-D1 molecule is present in an amount of 0.0001% by weight to 1% by weight of the supplement; and wherein the dried animal digest is present in an amount of 20% by weight to 80% by weight of the supplement.
6. System according to claim 5, characterized in that the food composition is cat food.

Description

CROSS-REFERENCE TO RELATED DEPOSIT REQUESTS [0001] This application claims the benefit of and priority over provisional application serial number U.S. 63/189,450, filed May 17, 2021, the disclosure of which is incorporated herein by reference in its entirety. BACKGROUND [0002] Approximately 20% of adults suffer from allergies to cats and/or cat dander. Symptoms of cat allergies range from mild rhinitis and conjunctivitis to life-threatening asthmatic responses, and cat allergies are a major obstacle to owning a cat. For example, cat allergy is the primary reason given by cat owners for returning cats to animal shelters. [0003] Most cat allergies are caused by a small, stable glycoprotein called Fel D1 (Feline domesticus allergen number 1). This protein is transferred to cat dander through the grooming process and becomes airborne. After inhaling cat dander carrying Fel D1, an allergic cascade is triggered with the recognition of Fel D1 by human immune cells. SUMMARY [0004] The present disclosure relates to supplements to reduce the allergic response to Fel D1. In general, the supplements can be given to a cat with or without additional food compositions. [0005] In one embodiment, a supplement to reduce the allergic response to Fel D1 may comprise an anti-Fel D1 antibody and an animal digest. [0006] In another embodiment, a method for manufacturing a supplement to reduce the allergic response to Fel D1 may comprise mixing an anti-Fel D1 antibody and an animal digest. [0007] In yet another embodiment, a system or kit for reducing the allergic response to Fel D1 may comprise a food composition and a supplement, the supplement comprising an anti-Fel D1 antibody and an animal digest. [0008] In yet another embodiment, a method of reducing human allergy symptoms in a cat may comprise administering orally to the cat an effective amount of a supplement, the supplement comprising an anti-Fel D1 antibody and an animal digest. [0009] Additional features and advantages are described in the present invention, and will become apparent from the detailed description that follows. DETAILED DESCRIPTION Definitions [0010] As used in this disclosure and the attached claims, the singular forms "a," "an," "the," and "the" include plural references unless the context clearly indicates otherwise. The words "comprise," "comprises," and "comprising" will be interpreted inclusively rather than exclusively. Similarly, the terms "include," "including," and "or" should all be interpreted inclusively unless such interpretation is clearly excluded by the context. However, the devices described herein may not have any element that is not specifically described. Thus, a disclosure of an embodiment that uses the term "that comprises" includes a disclosure of embodiments "that consist essentially of" and "that consist" of the aforementioned components. [0011] The term "and/or" used in the context of "X and/or Y" should be interpreted as "X," or "Y," or "X and Y." When used herein, the terms "example" and "such as," particularly when followed by a list of terms, are merely illustrative and exemplary and should not be considered exclusive or comprehensive. Any embodiment disclosed herein may be combined with any other embodiment disclosed herein, unless explicitly indicated otherwise. [0012] The ranges of values are used in the present invention in abbreviated form, to avoid mentioning each of the values within the range. Any suitable value within the range can be selected as the highest or lowest value of the range. Furthermore, numerical ranges in the present document include all integers, natural numbers, or fractions within the range. [0013] All percentages expressed in the present invention are expressed as a weight of the total weight of the composition, unless otherwise indicated. When reference is made to pH, the values correspond to pH measured at 25 °C with standard equipment. As used herein, the term "about" or "substantially," in reference to a number, is understood as referring to numbers in a range of numbers, for example, the range of -10% to +10%, -5% to +5%, -1% to +1%, or, in one aspect, -0.1% to +0.1% of the number mentioned. [0014] The term "allergy" is synonymous with "allergic response" or "allergic reaction." Each term refers to a state of intensity of immune response in a specific animal to an exogenous antigen (or "allergen") that is not otherwise harmful to the animal. A "symptom" of an allergic response refers to any measure of the intensity of the immune response, for example, at the molecular level (including the measurement of an activity or expression of a protein, or transcription or gene), at the cellular level, at the organ level, at the systemic level, or at the organism level. Such symptoms may comprise one or more of these levels. "Reducing at least one symptom" includes reducing such symptoms before they occur so that there are no symptoms for an allergic response and thus preventing the allergic response. I